Latira

Timolol maleate and latanoprost, the active ingredients in Latira, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They treat open‑angle glaucoma and ocular hypertension in adult patients by lowering intraocular pressure.

GNH USA supplies Latira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable global distribution for this prescription ophthalmic solution. Our network ensures timely delivery and regulatory compliance across multiple regions.

Latira is used in the management of ocular conditions that involve elevated intraocular pressure.

Open‑angle glaucoma: reduces intraocular pressure to protect the optic nerve and preserve visual field. Ocular hypertension: lowers intraocular pressure to prevent progression to glaucoma. Secondary glaucoma (e.g., pseudoexfoliative): helps control intraocular pressure when other therapies are insufficient.

The ocular formulation of Latira may cause a range of local and systemic adverse reactions.

Common Side Effects: - Blurred vision: transient visual disturbance after instillation. - Eye irritation or burning: mild discomfort at the site. - Conjunctival hyperemia: redness of the eye. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris pigmentation: gradual brown discoloration.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, itching, or rash requiring medical attention. - Systemic beta‑blocker effects: bradycardia, hypotension, bronchospasm in susceptible patients. - Corneal edema or ulceration: persistent pain or vision loss needing urgent care.

Before prescribing Latira, clinicians should consider several safety and handling precautions. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; evaluate risk versus benefit. - Contraindications: asthma, severe chronic obstructive pulmonary disease, bradycardia, second‑ or third‑degree heart block. - Systemic beta‑blocker therapy: monitor for additive cardiovascular depression. - Contact lens wearers: remove lenses before instillation to avoid discomfort. - Store at room temperature below 25 °C: keep in original container, protect from light and moisture.

Latira can interact with other systemic or ocular agents, requiring careful medication review.

Major Interactions (Avoid): - Other non‑selective beta‑blockers: may cause excessive bradycardia or hypotension. - Systemic antihypertensives (e.g., calcium channel blockers): increased risk of cardiovascular depression. - Epinephrine eye drops: antagonistic effect reducing efficacy of latanoprost.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may increase risk of corneal complications. - Other prostaglandin analogs: additive ocular side effects such as iris pigmentation. - Systemic carbonic anhydrase inhibitors: enhanced intraocular pressure lowering effect, monitor pressure.